文献速递头颈与中枢神经肿瘤

超突变胶质母细胞瘤的免疫基因组学:一例生殖系POLE缺陷患者接受检查点阻断免疫治疗

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.
PubMed 文献 · Cancer Discov · 2016-09-28

本文报告一例左额叶胶质母细胞瘤伴原始神经外胚层肿瘤特征及超突变基因型的患者,该患者存在POLE生殖系改变。在标准放化疗期间出现颈椎转移,随后接受帕博利珠单抗治疗,不久后出现新的脊柱转移灶。通过全外显子组DNA测序和克隆分析,报告了治疗过程中亚克隆结构的变化,并观察到所有肿瘤中持续高负荷的新抗原。开始帕博利珠单抗治疗后,随后切除的转移性脊柱病灶中观察到活跃的淋巴细胞浸润,一个进展性颅内病灶出现客观影像学缓解,提示检查点阻断治疗后中枢神经系统(CNS)免疫监视活跃。

要点

  • 一例POLE生殖系缺陷的超突变胶质母细胞瘤患者接受帕博利珠单抗治疗。
  • 治疗后切除的脊柱转移灶中观察到活跃淋巴细胞浸润。
  • 一个进展性颅内病灶出现客观影像学缓解,提示CNS免疫激活。

核心结论

  • 具有DNA修复缺陷的胶质母细胞瘤接受检查点阻断治疗可能导致CNS免疫激活,产生临床和免疫学上有意义的缓解。
  • 这些患者可能代表一个基因组分层群体,可考虑免疫治疗。

研究设计与样本

  • 病例报告:一例左额叶胶质母细胞瘤伴原始神经外胚层肿瘤特征及超突变基因型的患者,存在POLE生殖系改变。
  • 患者接受标准放化疗,期间出现颈椎转移,随后接受帕博利珠单抗治疗。
  • 使用全外显子组DNA测序和克隆分析,分析治疗过程中的亚克隆结构变化。

主要发现

  • 治疗过程中所有肿瘤中观察到持续高负荷的新抗原。
  • 开始帕博利珠单抗后,随后切除的转移性脊柱病灶中观察到活跃的淋巴细胞浸润。
  • 一个进展性颅内病灶出现客观影像学缓解。

临床怎么用

  • 作者认为,具有DNA修复缺陷的胶质母细胞瘤患者可能代表一个基因组分层群体,可考虑免疫治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: We present the case of a patient with a left frontal glioblastoma with primitive neuroectodermal tumor features and hypermutated genotype in the setting of a POLE germline alteration. During standard-of-care chemoradiation, the patient developed a cervical spine metastasis and was subsequently treated with pembrolizumab. Shortly thereafter, the patient developed an additional metastatic spinal lesion. Using whole-exome DNA sequencing and clonal analysis, we report changes in the subclonal architecture throughout treatment. Furthermore, a persistently high neoantigen load was observed within all tumors. Interestingly, following initiation of pembrolizumab, brisk lymphocyte infiltration was observed in the subsequently resected metastatic spinal lesion and an objective radiographic response was noted in a progressive intracranial lesion, suggestive of active central nervous system (CNS) immunosurveillance following checkpoint blockade therapy. SIGNIFICANCE: It is unclear whether hypermutated glioblastomas are susceptible to checkpoint blockade in adults. Herein, we provide proof of principle that glioblastomas with DNA-repair defects treated with checkpoint blockade may result in CNS immune activation, leading to clinically and immunologically significant responses. These patients may represent a genomically stratified group for whom immunotherapy could be considered. Cancer Discov; 6(11); 1230-6. ©2016 AACR.See related commentary by Snyder and Wolchok, p. 1210This article is highlighted in the In This Issue feature, p. 1197.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Johanns TM, Miller CA, Dorward IG, et al. Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discov. 2016. PMID: 27683556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。